References
Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2:927–937
Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY et al (2006) Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 20:1361–1367
Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA (1996) Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 10:40–42
O’Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE et al (1995) Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86:3322–3326
Luo CY, Tang JY, Wang YP (2004) Homoharringtonine: a new treatment option for myeloid leukemia. Hematology 9:259–270
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, X., Yang, C., Shao, K. et al. Refractory multiple myeloma treated with homoharringtonine: report of two cases. Ann Hematol 86, 919–921 (2007). https://doi.org/10.1007/s00277-007-0331-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-007-0331-5